Skip to content

Advertisement

  • Meeting abstract
  • Open Access

Quality of Life (QOL) improvement following catheter-based autologous bone marrow mononuclear cell transplantation (ABM-MCT)

  • 1,
  • 1,
  • 1,
  • 2,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Critical Care20037 (Suppl 3) :P83

https://doi.org/10.1186/cc2279

  • Published:

Keywords

  • Medical Outcome Study
  • Autologous Bone Marrow
  • Treadmill Test
  • Bone Marrow Mononuclear Cell
  • Reversibility Defect

Background

We have reported a pilot study of ABM-MCT to areas of ischemic myocardium [1], and in humans at 8 weeks follow-up after ABM-MCT ACC'03. The purpose of this study was to assess whether the changes in the QOL in patients with end-stage ischemic heart failure (ESIHF) submitted to catheter-based ABM-MCT persists in the 6 month follow-up.

Methods

A prospective assessment of the QOL before and 8 and 24 weeks after ABM-MCT guided by the NOGA system, targeting hibernating myocardium in ESIHF, using the Minnesota Living with Heart Failure Questionnaire and the Medical Outcomes Study Short Form-36. The cardiac evaluation included Canadian Cardiovascular Society class, VO2max on the treadmill test, ejection fraction and end systolic volume on two-dimensional echocardiogram and total reversibility defect on MIBI-SPECT.

Results

There were 14 patients (two females). The changes in parameters 8 and 24 weeks after the procedure are presented in Table 1. According to these objective data we observed a QOL improvement, based on the scores of Minnessota varying from 46 ± 19 to 30 ± 17 (P = 0.002) at 8 weeks and to 18 ± 14 (P = 0.003) at 24 weeks, and an increase of all eight dimensions of the Medical Outcomes Study Short Form-36 as presented in Table 2.
Table 1

:

 

Baseline

8 weeks

P

24 weeks

P

Canadian Cardiovascular Society class

2.64 ± 0.84

1.28 ± 0.61

0.0001

1.44 ± 0.5

0.003

Ejection fraction

30 ± 5

35 ± 8

0.029

32.4 ± 6

0.04

End systolic volume

147 ± 53

123 ± 48

0.02

139 ± 49

0.01

VO2max

17.96 ± 8.78

23.4 ± 8

0.01

24.4 ± 8

0.05

Total reversibility defect

15 ± 14

4.5 ± 10

0.02

  
Table 2

:

Medical Outcomes Study Short Form-36

Baseline

8 weeks

P

24 weeks

P

BP

39 ± 22

79 ± 27

0.0014

68 ± 30

0.03

MH

58 ± 21

74 ± 19

0.02

77 ± 20

0.02

GH

61 ± 19

77 ± 16

0.03

81 ± 21

0.05

PF

43 ± 26

68 ± 24

0.009

71 ± 26

0.03

RE

39 ± 49

58 ± 43

0.27

92 ± 15

0.06

RP

35 ± 42

65 ± 42

0.03

84 ± 27

0.06

SF

68 ± 26

74 ± 21

0.34

86 ± 14

0.04

VI

57 ± 22

74 ± 18

0.02

76 ± 19

0.08

Conclusion

The data suggest that ABM-MCT can improve the QOL of patients with ESIHF. Prospective studies with a greater number of patients will be necessary to confirm these initial data.

Authors’ Affiliations

(1)
Hospital Pró-Cardíaco, Rio de Janeiro, RJ, Brazil
(2)
Texas Heart Institute, 6770 Bertner Avenue, Houston, TX 77030, USA

References

  1. Eur J Nucl Med 2002, 29: 226A.Google Scholar

Copyright

Advertisement